Related Experiment Videos
[Clinical-therapeutic considerations in pertussis]
S Catania1, C Ajassa, D Summonti
1Istituto di Malattie Infettive, Università La Sapienza, Roma.
Rivista Europea Per Le Scienze Mediche E Farmacologiche = European Review for Medical and Pharmacological Sciences = Revue Europeenne Pour Les Sciences Medicales Et Pharmacologiques
|July 1, 1992
Summary
Early pertussis treatment with macrolides, betamethasone, and immunoglobulin G significantly reduces disease duration, fit severity, and contagion risk in infants and children.
Area of Science:
- Infectious Diseases
- Pediatrics
- Pharmacology
Context:
- Pertussis (whooping cough) remains a significant public health concern, particularly in pediatric populations.
- Observational study conducted at Policlinico Umberto I in Rome from 1987 to 1991.
- 171 cases of pertussis were analyzed.
Purpose:
- To evaluate the efficacy of a specific therapeutic protocol for pertussis.
- To determine the impact of early treatment initiation on disease outcomes.
- To assess the effectiveness of combined macrolide, betamethasone, and immunoglobulin G therapy.
Summary:
- A therapeutic protocol including macrolides (erythromycin or myocamicin), betamethasone, specific immunoglobulin G, and oxygen therapy was administered.
- Bronchodilators were added for severe asphyxiated fits in older children.
- The protocol demonstrated efficacy in shortening disease length and reducing fit severity.
Impact:
- Early initiation of this comprehensive treatment regimen is crucial for improving pertussis outcomes.
- The study highlights the importance of prompt medical intervention to mitigate disease severity and transmission.
- Findings support the effectiveness of the described multimodal approach in managing pertussis.